Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay

Carol D. Cheli, Deborah L. Morris, Linda Kish, Joan Goldblatt, Irene Neaman, W. Jeffrey Allard, Kwok K. Yeung, Alan H B Wu, Robert Moore, Daniel Wan-Yui Chan, Herbert A. Fritsche, Morton K. Schwartz, Donald L. Very

Research output: Contribution to journalArticle

Abstract

We conducted a multicenter evaluation of the analytical and clinical features of the automated Bayer Immuno 1(TM) CA 15-3(TM) assay and compared assay performance to two manual tests. Results of the 10-day imprecision study of the Bayer Immuno 1 assay pooled across four evaluation sites and three lots of reagent produced total CV ≤4%. Lot-to-lot reproducibility for 26 different lots of reagents and calibrators manufactured over a 2-year period was demonstrated (CV, 1.1%). Results for the Bayer Immuno 1 assay correlated well with the Biomira TRUQUANT® BR(TM) 27.29 and Centocor® CA 15-3 RIAs (r ≤0.94). The upper limit of the reference interval for the Bayer Immuno 1 assay was 35.9 kilounits/L (35.9 units/mL); values were similar for all methods. Longitudinal monitoring of healthy women yielded assay values with an average CV of 11% and 21% for the Bayer Immuno 1 and Biomira assays, respectively. The Bayer Immuno 1 assay demonstrated the analytical features, intermethod correlation, and long-term performance characteristics that are essential for longitudinal monitoring of breast cancer patients.

Original languageEnglish (US)
Pages (from-to)765-772
Number of pages8
JournalClinical Chemistry
Volume44
Issue number4
StatePublished - 1998

Fingerprint

Assays
Breast Neoplasms
TM 1
Monitoring

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Cheli, C. D., Morris, D. L., Kish, L., Goldblatt, J., Neaman, I., Allard, W. J., ... Very, D. L. (1998). Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay. Clinical Chemistry, 44(4), 765-772.

Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay. / Cheli, Carol D.; Morris, Deborah L.; Kish, Linda; Goldblatt, Joan; Neaman, Irene; Allard, W. Jeffrey; Yeung, Kwok K.; Wu, Alan H B; Moore, Robert; Chan, Daniel Wan-Yui; Fritsche, Herbert A.; Schwartz, Morton K.; Very, Donald L.

In: Clinical Chemistry, Vol. 44, No. 4, 1998, p. 765-772.

Research output: Contribution to journalArticle

Cheli, CD, Morris, DL, Kish, L, Goldblatt, J, Neaman, I, Allard, WJ, Yeung, KK, Wu, AHB, Moore, R, Chan, DW-Y, Fritsche, HA, Schwartz, MK & Very, DL 1998, 'Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay', Clinical Chemistry, vol. 44, no. 4, pp. 765-772.
Cheli CD, Morris DL, Kish L, Goldblatt J, Neaman I, Allard WJ et al. Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay. Clinical Chemistry. 1998;44(4):765-772.
Cheli, Carol D. ; Morris, Deborah L. ; Kish, Linda ; Goldblatt, Joan ; Neaman, Irene ; Allard, W. Jeffrey ; Yeung, Kwok K. ; Wu, Alan H B ; Moore, Robert ; Chan, Daniel Wan-Yui ; Fritsche, Herbert A. ; Schwartz, Morton K. ; Very, Donald L. / Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay. In: Clinical Chemistry. 1998 ; Vol. 44, No. 4. pp. 765-772.
@article{a661647423e14aceb669240fd8769a27,
title = "Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay",
abstract = "We conducted a multicenter evaluation of the analytical and clinical features of the automated Bayer Immuno 1(TM) CA 15-3(TM) assay and compared assay performance to two manual tests. Results of the 10-day imprecision study of the Bayer Immuno 1 assay pooled across four evaluation sites and three lots of reagent produced total CV ≤4{\%}. Lot-to-lot reproducibility for 26 different lots of reagents and calibrators manufactured over a 2-year period was demonstrated (CV, 1.1{\%}). Results for the Bayer Immuno 1 assay correlated well with the Biomira TRUQUANT{\circledR} BR(TM) 27.29 and Centocor{\circledR} CA 15-3 RIAs (r ≤0.94). The upper limit of the reference interval for the Bayer Immuno 1 assay was 35.9 kilounits/L (35.9 units/mL); values were similar for all methods. Longitudinal monitoring of healthy women yielded assay values with an average CV of 11{\%} and 21{\%} for the Bayer Immuno 1 and Biomira assays, respectively. The Bayer Immuno 1 assay demonstrated the analytical features, intermethod correlation, and long-term performance characteristics that are essential for longitudinal monitoring of breast cancer patients.",
author = "Cheli, {Carol D.} and Morris, {Deborah L.} and Linda Kish and Joan Goldblatt and Irene Neaman and Allard, {W. Jeffrey} and Yeung, {Kwok K.} and Wu, {Alan H B} and Robert Moore and Chan, {Daniel Wan-Yui} and Fritsche, {Herbert A.} and Schwartz, {Morton K.} and Very, {Donald L.}",
year = "1998",
language = "English (US)",
volume = "44",
pages = "765--772",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "4",

}

TY - JOUR

T1 - Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay

AU - Cheli, Carol D.

AU - Morris, Deborah L.

AU - Kish, Linda

AU - Goldblatt, Joan

AU - Neaman, Irene

AU - Allard, W. Jeffrey

AU - Yeung, Kwok K.

AU - Wu, Alan H B

AU - Moore, Robert

AU - Chan, Daniel Wan-Yui

AU - Fritsche, Herbert A.

AU - Schwartz, Morton K.

AU - Very, Donald L.

PY - 1998

Y1 - 1998

N2 - We conducted a multicenter evaluation of the analytical and clinical features of the automated Bayer Immuno 1(TM) CA 15-3(TM) assay and compared assay performance to two manual tests. Results of the 10-day imprecision study of the Bayer Immuno 1 assay pooled across four evaluation sites and three lots of reagent produced total CV ≤4%. Lot-to-lot reproducibility for 26 different lots of reagents and calibrators manufactured over a 2-year period was demonstrated (CV, 1.1%). Results for the Bayer Immuno 1 assay correlated well with the Biomira TRUQUANT® BR(TM) 27.29 and Centocor® CA 15-3 RIAs (r ≤0.94). The upper limit of the reference interval for the Bayer Immuno 1 assay was 35.9 kilounits/L (35.9 units/mL); values were similar for all methods. Longitudinal monitoring of healthy women yielded assay values with an average CV of 11% and 21% for the Bayer Immuno 1 and Biomira assays, respectively. The Bayer Immuno 1 assay demonstrated the analytical features, intermethod correlation, and long-term performance characteristics that are essential for longitudinal monitoring of breast cancer patients.

AB - We conducted a multicenter evaluation of the analytical and clinical features of the automated Bayer Immuno 1(TM) CA 15-3(TM) assay and compared assay performance to two manual tests. Results of the 10-day imprecision study of the Bayer Immuno 1 assay pooled across four evaluation sites and three lots of reagent produced total CV ≤4%. Lot-to-lot reproducibility for 26 different lots of reagents and calibrators manufactured over a 2-year period was demonstrated (CV, 1.1%). Results for the Bayer Immuno 1 assay correlated well with the Biomira TRUQUANT® BR(TM) 27.29 and Centocor® CA 15-3 RIAs (r ≤0.94). The upper limit of the reference interval for the Bayer Immuno 1 assay was 35.9 kilounits/L (35.9 units/mL); values were similar for all methods. Longitudinal monitoring of healthy women yielded assay values with an average CV of 11% and 21% for the Bayer Immuno 1 and Biomira assays, respectively. The Bayer Immuno 1 assay demonstrated the analytical features, intermethod correlation, and long-term performance characteristics that are essential for longitudinal monitoring of breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=15644375823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15644375823&partnerID=8YFLogxK

M3 - Article

C2 - 9554487

AN - SCOPUS:15644375823

VL - 44

SP - 765

EP - 772

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 4

ER -